GPT-Rosalind is OpenAI's first domain-specific model, built for drug discovery and life sciences—and it's not for everyone.

The partnership will enable Novo to better use AI to analyze complex datasets, and identify promising new drugs.

Novo Nordisk partners with OpenAI to accelerate drug discovery using AI across research manufacturing and operations globally ...

OpenAI is granting a select group of users access to a new artificial intelligence model designed to identify software security vulnerabilities. This strategic move comes just one week after rival ...

Several attacks involving OpenAI’s chatbot—including Tumbler Ridge and FSU—raise urgent questions about the technology.

OpenAI Has a New AI Model Built for Biology and Science ...

AI giant said its security system has already contributed to more than 3,000 vulnerability fixes since its private beta ...

Cyber, a fine-tuned variant of its GPT-5.4 model designed for defensive cybersecurity work and also announced a significant ...

The company’s Claude Mythos Preview model is remarkably good at harming or hijacking other systems. Anthropic’s first ...

Danish drugmaker Novo Nordisk is partnering with ChatGPT's parent company, OpenAI, to bring ‘better treatment options’ for ...

OpenAI rolled out their updated Codex app for Mac yesterday and, among other things, they shipped a native computer use tool ...